<DOC>
	<DOCNO>NCT00402766</DOCNO>
	<brief_summary>Primary Objective : - To determine maximum tolerate dose combination cisplatin , imatinib mesylate , pemetrexed metastatic malignant mesothelioma . Secondary Objectives : - To explore biologic effect cisplatin , imatinib mesylate , pemetrexed tumor tissue : - histologic analysis biopsy tissue - non-invasive assessment tumor vascularity perform , treatment - electron microscopy analysis endothelial cell architecture patient treatment imatinib mesylate - To explore effect cisplatin , imatinib mesylate , pemetrexed surrogate marker serum . - To assess rate response therapy . - To determine dos combination regimen cisplatin , imatinib mesylate , pemetrexed enable de-phosphorylation platelet derive growth factor receptor ( PDGF-R ) malignant mesothelioma tumor cell . - To determine pharmacokinetic interaction agent combination regimen .</brief_summary>
	<brief_title>Cisplatin , Pemetrexed , Imatinib Mesylate Malignant Mesothelioma</brief_title>
	<detailed_description>Cisplatin use treat different cancer , include testicular , germ cell , head neck , bladder , lung cancer . This drug atom-containing platinum , design poison cancer cell , cause die . Pemetrexed design block enzyme body play part tumor growth . Imatinib mesylate drug block certain protein play part development cancer . Imatinib mesylate also show increase effect chemotherapy tumor cell . Before start treatment study , call `` screening test . '' These test help doctor decide eligible take part study . You complete medical history record physical exam , include measurement vital sign ( temperature , pulse , breathe rate , blood pressure ) weight . An ECOG performance status evaluation ( test look ability perform day-to-day activity ) do . Blood drawn ( 3 4 teaspoon ) needle vein routine test . You ask medication take . Women able child must negative blood pregnancy test . Also , tumor evaluate magnetic resonance imaging ( MRI ) computerize tomography ( CT ) scan start study . If find eligible take part study , begin take imatinib mesylate . Depending begin treatment study , may ask take 3 , 4 , 6 tablet imatinib mesylate mouth day . Your doctor also ask take folic acid tablet ( multivitamin folic acid ) week receive first infusion pemetrexed every day study . You also give injection vitamin B12 . The vitamin B12 shot repeat every 9 week treatment study . Folic acid vitamin B12 help decrease risk severe side effect pemetrexed . After 1 week imatinib mesylate folic acid , receive cisplatin pemetrexed IV infusion . Cisplatin ( give 2 hour ) pemetrexed ( give 40 minute ) give first day treatment cycle total 6 cycle . Each cycle 28 day long . Dexamethasone also give vein receive pemetrexed . Dexamethasone help decrease risk rash nausea may cause pemetrexed . Your doctor also ask take dexamethasone tablet mouth twice day ( 12 hour apart ) Day 2 cycle . Every 4 week , physical exam , include measurement vital sign weight . You also performance status evaluation . Blood drawn ( 3 4 teaspoon ) needle vein routine test . Also , every 8 week , tumor measure CT MRI scan . After complete 6 treatment cycle cisplatin pemetrexed , continue take imatinib mesylate tablet every day 1 month 6 treatment cycle . If develop intolerable side effect disease get bad , treatment study may delay ; dose study drug decrease side effect go ; may take completely study . Your doctor talk change dose schedule dos medication evaluate clinic . After complete treatment , call end-of-study visit . At visit , physical exam , include measurement vital sign weight . You ECOG performance status evaluation . You blood draw ( 3 4 teaspoon ) need vein routine test . You also tumor measure CT MRI scan . This investigational study . Both cisplatin pemetrexed approve FDA treatment malignant mesothelioma . The FDA approve imatinib mesylate treatment leukemia certain sarcoma ; however , authorize FDA use research treatment malignant mesothelioma . Up 42 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Folic Acid Antagonists</mesh_term>
	<criteria>1 . A write , voluntary inform consent form must complete prior begin study procedure . 2 . Patients &gt; /= 18 year age . 3 . Histologically documented diagnosis malignant mesothelioma . 4 . Performance status 02 ( ECOG ) 5 . Patients must adequate hepatic , renal , &amp; bone marrow function , define following : ( 1 ) total bilirubin &lt; /=1.5xULN ; ( 2 ) serum glutamate oxaloacetate transaminase ( SGOT ) &amp; serum glutamate pyruvate transaminase ( SGPT ) &lt; /=2.5xULN ; ( 3 ) creatinine &lt; /= 1.5xULN ; ( 4 ) ANC &gt; /= 1.5x10^9/L ; ( 5 ) platelet &gt; /=100 x 10^9/L.Note : Renal function base serum creatinine level &lt; /= 1.5xULN.The standard Cockcroft &amp; Gault formula measure glomerular filtration rate ( GFR ) use appropriate radio label method ( 51CrEDTA Tc99mDTPA ) must use calculate cranial cruciate ligament ( CrCl ) enrollment dosing.The method use @ baseline use throughout study.CrCl &gt; /= 45mg/dl . 6 . Female patient childbearing potential must negative pregnancy test within 7 day initiation study drug dosing . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Male female patient reproductive potential must agree employ effective barrier method birth control throughout study 3 month follow discontinuation study drug . 7 . Patients receive prior chemotherapy metastatic recurrent unresectable malignant mesothelioma ; exception patient recurrent mesothelioma induction chemotherapy follow definitive treatment ( surgery +/ radiotherapy ) . Patients must 2 few cycles/doses induction chemotherapy must tumor response induction therapy . 8 . Patients must document unresectable malignant mesothelioma ( pleural peritoneal ) . 9 . Patients treat brain metastasis stable brain disease ( i.e . steroid least 4 week prior study enrollment ) . 1 . Patient receive investigational agent within 28 day first day study drug dose . 2 . Patient &lt; /= 5 year free another primary malignancy except : primary malignancy currently clinically significant require active intervention , primary malignancy basal cell skin cancer , squamous skin cancer , cervical carcinoma situ . 3 . Patient Grade III/IV cardiac problem define New York Heart Association Criteria . ( i.e. , congestive heart failure ) 4 . Patients myocardial infarction within 6 month study . 5 . Female patient pregnant breastfeeding . 6 . Patient severe and/or uncontrolled medical disease ( i.e. , uncontrolled diabetes , chronic renal disease , active uncontrolled infection ) . 7 . Patient know untreated unstable brain metastasis . 8 . Patient know chronic liver disease ( i.e. , chronic active hepatitis , cirrhosis ) . 9 . Patient known diagnosis human immunodeficiency virus ( HIV ) infection . HIV patient much great risk infection receive highly myelosuppressive agent ( cisplatin , pemetrexed , imatinib ) safety reason eligible trial . 10 . Patient receive prior chemotherapy malignant mesothelioma exception list inclusion criterion # 7 . 11 . Patient previously receive radiotherapy &gt; /= 25 % bone marrow . 12 . Patient major surgery within 2 week prior study entry . 13 . Patient significant history noncompliance medical regimen inability grant reliable informed consent . 14 . Patients must agree use herbal remedy overthecounter biologics ( i.e . shark cartilage ) . 15 . Prior exposure imatinib mesylate . 16 . Patients take therapeutic level warfarin . However , patient receive 1 mg daily catheter relate anticoagulation eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Mesothelioma</keyword>
	<keyword>Pleural Mesothelioma</keyword>
	<keyword>Peritoneal Mesothelioma</keyword>
	<keyword>PDGF-R</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Alimta</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Imatinib Mesylate</keyword>
	<keyword>Gleevec</keyword>
	<keyword>Platinol</keyword>
	<keyword>Platinol-AQ</keyword>
	<keyword>CDDP</keyword>
	<keyword>Ly231514</keyword>
	<keyword>Multitargeted Antifolate</keyword>
	<keyword>NSC-698037</keyword>
	<keyword>STI571</keyword>
	<keyword>NSSC-716051</keyword>
</DOC>